Lv51
880 积分 2023-06-14 加入
TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2
2小时前
已完结
YOSEMITE and RHINE: Phase 3 Randomized Clinical Trials of Faricimab for Diabetic Macular Edema: Study Design and Rationale
2小时前
已完结
Efficacy, durability and safety of faricimab for patients with neovascular age-related macular degeneration: 48-week results from the phase 3 LUCERNE China subpopulation
2小时前
已完结
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
2小时前
已完结
Discovery and Characterization of a Bicyclic Peptide (Bicycle) Binder to Thymic Stromal Lymphopoietin
3个月前
已完结
JAK inhibitor selectivity: new opportunities, better drugs?
4个月前
已完结
Current application status and structure–activity relationship of selective and non-selective JAK inhibitors in diseases
4个月前
已完结
Biopharma dealmaking in 2022
4个月前
已完结
Biopharma dealmaking in 2023
4个月前
已完结
Leucine as an excipient in spray dried powder for inhalation
5个月前
已完结
皖公网安备34019202002308
